Biosimilar Doubleheader: Amgen's Humira Competitor Pitching First To FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Arthritis Advisory Committee will preside at back-to-back biosimilar reviews for Amgen's ABP 501 and Sandoz's GP2015, which references Enbrel, in mid-July.